Better Therapeutics, Inc. Common Stock
BTTX
BTTX was delisted on the 15th of March, 2024.
26 hedge funds and large institutions have $40.9M invested in Better Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
1,800% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 1
225% more funds holding
Funds holding: 8 → 26 (+18)
187% more capital invested
Capital invested by funds: $14.3M → $40.9M (+$26.6M)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$4.25M |
| 2 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$3.48M |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$3.48M |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$3.08M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSU
Mizuho Securities USA
New York
|
-$1.86M |
| 2 |
GCL
Glazer Capital LLC
New York
|
-$1.38M |
| 3 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$26.9K |
BTTX Hedge Fund Activity: Q2 2021 in Review
26 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q2 2021, worth a combined $40.9M — up 187% from $14.3M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new BTTX positions and 1 closed out — a net gain of 18 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $4.25M. The largest seller was Mizuho Securities USA, exiting entirely with an estimated $1.86M sold.
- 26 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q2 2021, up from 8 in Q1 2021.
- Funds reported $40.9M of Better Therapeutics, Inc. Common Stock stock for Q2 2021, up 187% quarter-over-quarter.
- 19 funds opened new Better Therapeutics, Inc. Common Stock positions in Q2 2021 and 1 closed out, a net change of +18 holders.
- The largest Better Therapeutics, Inc. Common Stock buyer in Q2 2021 was Boothbay Fund Management, an estimated $4.25M added.
- The largest Better Therapeutics, Inc. Common Stock seller in Q2 2021 was Mizuho Securities USA, an estimated $1.86M sold.
Based on aggregated 13F filings for Q2 2021.